Prostate cancer hijacks the normal prostate's growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers. The discovery, published Dec. 13 in ...
Chinese NMPA approves Bayer’s oral ARi Nubeqa in combo with ADT for use in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, February 4, 2026, 14:00 ...
A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...
A TTUHSC research team led by Srinivas Nandana, Ph.D., (center) and Manisha Tripathi, Ph.D., (left) recently completed a study focused on uncovering the molecular and signaling mechanisms that drive ...
Italy: Patients with prostate cancer receiving maximal androgen blockade therapy face a significantly higher risk of bone ...
Evaluating survival post-7 mo PSA response, stratified by response, disease extent, and intermittent vs. continuous ADT in mHSPC: The S9346 trial. No AR alteration (n=326) AR alteration present (n=225 ...
Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study ...
The investigational drug BMS-986365 may help patients with mCRPC previously treated with ARPIs overcome drug resistance, despite their genomic status. The investigational dual androgen receptor ...
This figure shows the structure of PTGES3. The research team made the association after creating a fluorescent tag that tracks androgen receptor levels in real time. The androgen receptor is a hormone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results